BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $ASND readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07081997-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~PaTHway60 readout (P3) · Ascendis Pharma Bone Diseases A/S $ASND
DESCRIPTION:A Phase 3 Randomized Clinical Trial to Investigate the Safety a
 nd Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adu
 lt Participants With Hypoparathyroidism\n\nPrimary completion date: 2027-0
 6 (estimated) — month only\, shown on the 1st\nOriginally planned: 2026-
 12 (+6.0 months)\nPhase 3 · Cardio-Met · Hypoparathyroidism\, Endocrine 
 System Diseases\, Parathyroid Diseases\nEnrollment: 36 · Sites: 10\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT07081997\nhttps://clinicaltrials.gov/study/NCT07081997
URL:https://datacutoff.com/radar.html?nct=NCT07081997
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706764-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~Palopegteriparatide readout (P3) · Ascendis Pharma A/S $ASND
DESCRIPTION:A Study to Test the Effects and Safety of Palopegteriparatide i
 n Adolescents With Long-term Hypoparathyroidism\n\nPrimary completion date
 : 2027-08 (estimated) — month only\, shown on the 1st\nPhase 3 · Cardio
 -Met · Hypoparathyroidism\nEnrollment: 12 · Sites: 3\n\nPrimary completi
 on = last participant's primary-endpoint data collected\; topline results 
 usually follow weeks to months later. Sponsor-reported\, often an estimate
 . Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=
 NCT07706764\nhttps://clinicaltrials.gov/study/NCT07706764
URL:https://datacutoff.com/radar.html?nct=NCT07706764
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06732895-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~teACH readout (P2) · Ascendis Pharma A/S $ASND
DESCRIPTION:A Clinical Trial to Evaluate Efficacy and Safety of Navepegriti
 de in Adolescents (12 - 18 Years of Age) With Achondroplasia.\n\nPrimary c
 ompletion date: 2027-09 (estimated) — month only\, shown on the 1st\nOri
 ginally planned: 2026-12 (+9.0 months)\nPhase 2 · Rare · Achondroplasia\
 nEnrollment: 25 · Sites: 5\n\nPrimary completion = last participant's pri
 mary-endpoint data collected\; topline results usually follow weeks to mon
 ths later. Sponsor-reported\, often an estimate. Not investment advice.\n\
 nhttps://datacutoff.com/radar.html?nct=NCT06732895\nhttps://clinic
 altrials.gov/study/NCT06732895
URL:https://datacutoff.com/radar.html?nct=NCT06732895
CATEGORIES:Rare,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
